These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1387025)

  • 1. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.
    Matsuno H; Uematsu T; Umemura K; Takiguchi Y; Wada K; Nakashima M
    Br J Pharmacol; 1992 Jul; 106(3):533-8. PubMed ID: 1387025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
    Takiguchi Y; Asai F; Wada K; Nakashima M
    Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model.
    Nishiyama H; Umemura K; Saniabadi AR; Takiguchi Y; Uematsu T; Nakashima M
    Eur J Pharmacol; 1994 Oct; 264(2):191-8. PubMed ID: 7851482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2.
    Takiguchi Y; Wada K; Nakashima M
    Thromb Haemost; 1992 Oct; 68(4):460-3. PubMed ID: 1448780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
    Guth BD; Müller TH
    Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model.
    Umemura K; Wada K; Uematsu T; Nakashima M
    Stroke; 1993 Jul; 24(7):1077-81; discussion 1081-2. PubMed ID: 8322383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat.
    Umemura K; Kawai H; Ishihara H; Nakashima M
    Jpn J Pharmacol; 1995 Mar; 67(3):253-8. PubMed ID: 7630043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model.
    Matsuno H; Uematsu T; Nagashima S; Nakashima M
    J Pharmacol Methods; 1991 Jul; 25(4):303-17. PubMed ID: 1909407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates.
    Matsuno H; Kozawa O; Nagashima S; Kanamaru M; Uematsu T
    Br J Pharmacol; 1999 Jul; 127(5):1129-34. PubMed ID: 10455258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacodynamics and pharmacokinetics of a novel thromboxane receptor blocking drug vapiprost (GR32191) after single intravenous doses in healthy subjects.
    Thomas M; Keery RJ; Charter MK; Scully NL; Chilton JE; Lumley P
    Br J Clin Pharmacol; 1991 Aug; 32(2):181-6. PubMed ID: 1834144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on tPA-induced thrombolysis in a rabbit model of femoral arterial thrombosis.
    Fujita T; Hasan S; Storer BL; Shebuski RJ
    Fundam Clin Pharmacol; 1989; 3(6):643-53. PubMed ID: 2533138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arterial thrombosis model with photochemical reaction in guinea-pig and its property.
    Takiguchi Y; Hirata Y; Wada K; Nakashima M
    Thromb Res; 1992 Aug; 67(4):435-45. PubMed ID: 1412222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
    Horie S; Yamada M; Satoh M; Noritake S; Hiraishi S; Kizaki K; Kurusu O; Nakahara T; Ishii H; Kazama M
    Biol Pharm Bull; 1997 Jun; 20(6):625-31. PubMed ID: 9212979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of GR144053, a fibrinogen-receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tPA in the injured carotid artery of the hamster.
    Matsuno H; Kozawa O; Niwa M; Ito T; Tanabe K; Nishida M; Hayashi H; Uematsu T
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):191-7. PubMed ID: 9700979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery.
    Kaida T; Matsuno H; Niwa M; Kozawa O; Miyata H; Uematsu T
    Thromb Haemost; 1997 Mar; 77(3):562-7. PubMed ID: 9066011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers.
    Uematsu T; Nagashima S; Mizuno A; Hirano K; Nakashima M
    J Clin Pharmacol; 1991 Sep; 31(9):815-22. PubMed ID: 1839540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis.
    Shebuski RJ; Storer BL; Fujita T
    Thromb Res; 1988 Dec; 52(5):381-92. PubMed ID: 3146820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional vascular responses to thromboxane A2 analogue and their blockade with vapiprost, a selective thromboxane receptor blocking drug, in anesthetized dogs.
    Noguchi K; Ojiri Y; Chibana T; Matsuzaki T; Sakanashi M
    Jpn J Pharmacol; 1992 Dec; 60(4):341-8. PubMed ID: 1287269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
    Higo K; Karasawa A; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1251-5. PubMed ID: 1815525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.